These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 32827212)

  • 1. Organized immune cell interactions within tumors sustain a productive T-cell response.
    Cardenas MA; Prokhnevska N; Kissick HT
    Int Immunol; 2021 Jan; 33(1):27-37. PubMed ID: 32827212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells.
    Goc J; Germain C; Vo-Bourgais TK; Lupo A; Klein C; Knockaert S; de Chaisemartin L; Ouakrim H; Becht E; Alifano M; Validire P; Remark R; Hammond SA; Cremer I; Damotte D; Fridman WH; Sautès-Fridman C; Dieu-Nosjean MC
    Cancer Res; 2014 Feb; 74(3):705-15. PubMed ID: 24366885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognate memory CD4+ T cells generated with dendritic cell priming influence the expansion, trafficking, and differentiation of secondary CD8+ T cells and enhance tumor control.
    Hwang ML; Lukens JR; Bullock TN
    J Immunol; 2007 Nov; 179(9):5829-38. PubMed ID: 17947656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
    Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
    Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets.
    Tel J; Schreibelt G; Sittig SP; Mathan TS; Buschow SI; Cruz LJ; Lambeck AJ; Figdor CG; de Vries IJ
    Blood; 2013 Jan; 121(3):459-67. PubMed ID: 23212525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD8-mediated type 1 antitumor responses selectively modulate endogenous differentiated and nondifferentiated T cell localization, activation, and function in progressive breast cancer.
    Dobrzanski MJ; Reome JB; Hylind JC; Rewers-Felkins KA
    J Immunol; 2006 Dec; 177(11):8191-201. PubMed ID: 17114496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis.
    Li F; Sun Y; Huang J; Xu W; Liu J; Yuan Z
    Cancer Med; 2019 Dec; 8(17):7330-7344. PubMed ID: 31631566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism.
    Xu S; Koski GK; Faries M; Bedrosian I; Mick R; Maeurer M; Cheever MA; Cohen PA; Czerniecki BJ
    J Immunol; 2003 Sep; 171(5):2251-61. PubMed ID: 12928369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of melanoma growth after treatment with dendritic cells in a Tyr-SV40E murine model requires CD4+ T cells but not CD8+ T cells.
    Milling SW; Sai T; Silvers WK; Mintz B
    Melanoma Res; 2004 Dec; 14(6):555-62. PubMed ID: 15577330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.
    Reiser J; Banerjee A
    J Immunol Res; 2016; 2016():8941260. PubMed ID: 27314056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
    Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
    Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced CD5 on CD8
    Alotaibi F; Vincent M; Min WP; Koropatnick J
    Front Immunol; 2020; 11():584937. PubMed ID: 33584650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CTLA4 blockade maximizes antitumor T-cell activation by dendritic cells presenting idiotype protein or opsonized anti-CD20 antibody-coated lymphoma cells.
    Hsu FJ; Komarovskaya M
    J Immunother; 2002; 25(6):455-68. PubMed ID: 12439343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common gamma-chain cytokines.
    Anichini A; Scarito A; Molla A; Parmiani G; Mortarini R
    J Immunol; 2003 Aug; 171(4):2134-41. PubMed ID: 12902520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral Tcf1
    Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
    Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8(+) and CD4(+) T Cells.
    Yin W; Gorvel L; Zurawski S; Li D; Ni L; Duluc D; Upchurch K; Kim J; Gu C; Ouedraogo R; Wang Z; Xue Y; Joo H; Gorvel JP; Zurawski G; Oh S
    EBioMedicine; 2016 Mar; 5():46-58. PubMed ID: 27077111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity.
    Donia M; Andersen R; Kjeldsen JW; Fagone P; Munir S; Nicoletti F; Andersen MH; Thor Straten P; Svane IM
    Cancer Res; 2015 Sep; 75(18):3747-59. PubMed ID: 26183926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysfunction of antigen processing and presentation by dendritic cells in cancer.
    Bandola-Simon J; Roche PA
    Mol Immunol; 2019 Sep; 113():31-37. PubMed ID: 29628265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Origins and functional basis of regulatory CD11c+CD8+ T cells.
    Vinay DS; Kim CH; Choi BK; Kwon BS
    Eur J Immunol; 2009 Jun; 39(6):1552-63. PubMed ID: 19499519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.